secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2026-08-03T20:10:16+00:00
Accession:  0001193125-26-330568
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC initiates Himalayas-1 Phase 3 trial for rinzimetostat; Q2 cash $387.6M, R&D $36.3M
--------------------------------------------------------------------------------

- Initiated Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC; ~600 patients, 25 countries, primary endpoint rPFS.
- Entered clinical trial collaboration with Bayer to supply darolutamide at no cost for Himalayas-1; ORIC retains full rights to rinzimetostat.
- Cash and investments $387.6M as of June 30, 2026; includes $59.9M net proceeds from ATM; runway into 2H 2028.
- R&D expenses $36.3M for Q2 2026, up from $30.5M YoY; G&A $9.0M, up from $8.5M.
- Anticipated milestones: rinzimetostat program update 2H 2026; enozertinib data at ESMO October 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526330568/0001193125-26-330568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312526330568/oric-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-330568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer